KAPA - Kairos Pharma, Ltd. News

Sectors

KAPA

Kairos Pharma, Ltd.

0.24

900 x 0.24

200 x 0.25

bid

ask

0.00

1.22%

550 @ 07:50 PM

0.25 +0.01 (2.50%)

Ytd	-66.20%
1y	-82.22%

0.23

day range

0.25

0.22

52 week range

2.11

Open	0.24	Prev Close	0.24	Low	0.23	High	0.25	Mkt Cap	5.69M
Vol	374.71K	Avg Vol	2.21M	EPS	-1.98	P/E	N/A	Forward P/E	-7.46
Beta	1.56	Short Ratio	0.13	Inst. Own	0.10%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	N/A	50-d Avg	0.33	200-d Avg	0.57	1yr Est	9.00

KAPA News

benzinga.com

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 50.7% to $3.27 during Thursday's after-market

benzinga.com

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular sess

benzinga.com

Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Slip Ahead of Data-Heavy Week, Nvidia Ear

U.S. stock futures were mixed on Monday, as the Dow Jones index rose, the S&P 500 and Nasdaq 100

benzinga.com

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-ma

benzinga.com

Applied Optoelectronics, PDD Holdings And 3 Stocks To Watch Heading Into Monday

U.S. stock futures up, PDD, AAOI, and XPEV to report earnings, KAPA announces reverse stock split, G

benzinga.com

Kairos Pharma Announces 1-For-7 Reverse Stock Split, Effective Sept. 1

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming ca

businesswire.com

Kairos Pharma Announces 1-for-7 Reverse Stock Split

LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage

benzinga.com

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares moved upwards by 24.0% to $1.71 during Wednesday

benzinga.com

Kairos Pharma Partners With Bayer To Mull ENV-105 Inhibitor In Combination With Bayer’s XOFIGO

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on ove

businesswire.com

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic

LOS ANGELES--(BUSINESS WIRE)---- $KAPA #Bayer--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical

benzinga.com

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s

benzinga.com

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session

benzinga.com

Why JB Hunt Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

JB Hunt Transport Services Inc (JBHT) beat earnings and revenue estimates, causing shares to surge 7

benzinga.com

Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving?

Kairos Pharma shares surged 22.64% after hours following positive interim safety data from its lead

newsfilecorp.com

CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever

Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - CEO.CA ("CEO.CA"), the leading investor social

businesswire.com

Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated L

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmac

zacks.com

All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy

Kairos Pharma, Ltd. (KAPA) might move higher on growing optimism about its earnings prospects, which

newsfilecorp.com

Kapa Gold Announces the Results of Its 2026 Annual General Meeting

Vancouver, British Columbia--(Newsfile Corp. - June 19, 2026) - KAPA GOLD INC. (TSXV: KAPA) ("Kapa"

businesswire.com

Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to S

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmace

businesswire.com

Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmace

newsfilecorp.com

Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI

Los Angeles, California--(Newsfile Corp. - May 13, 2026) - Kairos Pharma, Ltd. (NYSE American: KAPA)

businesswire.com

Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filing

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmac

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

globenewswire.com

KAPA Investors Have Opportunity to Join Kairos Pharma, Ltd. Fraud Investigation with the Schall Law

LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights

businesswire.com

Kairos Pharma Recognized with Pinnacle Award for Excellence in Healthcare Innovation

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmace

businesswire.com

Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire Abou

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an inve

businesswire.com

Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Inv

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an inve

benzinga.com

Kairos Pharma Q4 EPS $(0.07) Beats $(0.10) Estimate

Kairos Pharma (AMEX:KAPA) reported quarterly losses of $(0.07) per share which beat the analyst cons

benzinga.com

Kairos Pharma Enters Into Binding Terms To Acquire CL-273 From Celyn Therapeutics For Undisclosed Su

The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expand

businesswire.com

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmac

benzinga.com

12 Health Care Stocks Moving In Thursday's After-Market Session

benzinga.com

Kairos Pharma Signs Deal To Acquire Two Experimental Lung Cancer Drug Candidates From Celyn Therapeu

Kairos Pharma, Ltd. (NYSE: KAPA), a clinical-stage biopharmaceutical company focused on innovative c

benzinga.com

12 Health Care Stocks Moving In Thursday's Pre-Market Session

businesswire.com

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmac

benzinga.com

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Thursday's Intraday Session

businesswire.com

Kairos Pharma to Present at 3rd Annual DealFlow Discovery Conference

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmace

businesswire.com

Kairos Pharma Wins 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmace

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com

D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintai

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com

D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintai

businesswire.com

Kairos Pharma Provides Shareholder Update

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmace

benzinga.com

D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintai

businesswire.com

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society M

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmac

benzinga.com

D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintai

benzinga.com

Kairos Pharma To Present Phase 2 Data On Apalutamide And Carotuximab In Advanced Prostate Cancer At

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company dedicated to addressing

benzinga.com

12 Health Care Stocks Moving In Friday's Intraday Session

benzinga.com

D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:KAPA) with a Buy and maintai